Physician profile
Saul Arber
NPI 1407800949
$2,218.40
in general payments reported to CMS, 2019-2025
38 companies · $25.52 in 2025
The $25.52 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $506 · 2021: $90.87 · 2022: $249 · 2023: $75.00 · 2025: $25.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $274.34 | 2019-2022 | |
| Janssen Biotech, INC. | $273.59 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $159.29 | 2019-2021 | |
| Pfizer INC. | $125.00 | 2019 | |
| Melinta Therapeutics, LLC | $119.33 | 2019 | |
| Sunovion Pharmaceuticals INC. | $104.70 | 2019 | |
| Tesaro, INC. | $101.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $83.67 | 2019-2020 | |
| Gilead Sciences, INC. | $75.00 | 2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $74.46 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $73.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $62.47 | 2019-2020 | |
| Amgen INC. | $49.20 | 2019-2020 | |
| Seagen INC. | $48.64 | 2020 | |
| Novartis Pharmaceuticals Corporation | $45.66 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $42.79 | 2019-2020 | |
| Genzyme Corporation | $41.33 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.63 | 2019 | |
| Janssen Scientific Affairs, LLC | $34.00 | 2019 | |
| Boston Scientific Corporation | $25.52 | 2025 | Spaceoar Vue System - 10ml |
| Regeneron Healthcare Solutions, INC. | $24.63 | 2019 | |
| Shionogi INC | $24.21 | 2021 | |
| Incyte Corporation | $24.17 | 2019 | |
| Insmed, INC. | $24.09 | 2020 | |
| Heron Therapeutics, INC. | $23.94 | 2019 | |
| Eisai INC. | $22.34 | 2020 | |
| Verastem, INC. | $21.70 | 2020 | |
| Shire North American Group INC | $20.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.92 | 2019 | |
| Taiho Oncology, INC. | $19.56 | 2019 | |
| Celgene Corporation | $19.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.98 | 2019 | |
| Phadia US INC. | $18.75 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $18.73 | 2019 | |
| Allergan, INC. | $17.39 | 2020 | |
| Merck Sharp & Dohme LLC | $16.92 | 2019 | |
| Astellas Pharma US INC | $16.67 | 2020 | |
| La Jolla Pharmaceutical Company | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Arber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.